Jazz Pharma (JAZZ)'s 841% Price Increase On A Sleep Drug Could Attract Attention From Capitol Hill
11/3/2016 6:47:59 AM
Shares of Jazz Pharmaceuticals PLC, an Irish-based biopharmaceutical company primarily focused on the development of therapies to treat sleep disorders, fell 10% in October, based on data from S&P Global Market Intelligence.
Although it was a pretty quiet month in terms of press releases for Jazz, the culprit appears to be pricing concerns for its lead drug, Xyrem.
One campaign issue that's gained a lot of press since September 2015 is prescription-drug reform.
comments powered by